Table 1.
Group characterization before oral zinc supplementation with different concentrations (CG = placebo; G1 = 5 mg-Zn/day; G2 = 10 mg-Zn/day).
| Group | CG | G1 | G2 | p 1 |
|---|---|---|---|---|
| n | 24 | 24 | 23 | -- |
| Age (years) | 8.4 (0.5) | 8.1 (1.0) | 9.1 (0.5) | <0.001 |
| Serum zinc (μg/mL) | 0.92 (0.13) | 1.01 (0.12) | 0.90 (0.11) | 0.007 |
| WAZ | −0.15 (0.79) | −0.85 (0.82) | −0.43 (1.05) | 0.031 |
| HAZ | 0.26 (0.98) | −0.64 (0.82) | −0.39 (1.19) | 0.008 |
| BAZ | −0.47 (0.74) | −0.70 (0.68) | −0.27 (0.75) | 0.142 |
| Resistance (Ω) | 773 (41) | 807 (65) | 748 (91) | 0.017 |
| R/H (Ω/cm) | 590.1 (41.7) | 654.4 (73.3) | 576.0 (87.8) | 0.001 |
| Reactance (Ω) | 71 (8) | 75 (9) | 68 (6) | 0.008 |
| Xc/H (Ω/cm) | 54.3 (7.2) | 60.8 (7.9) | 52.2 (6.4) | <0.001 |
| Phase angle (°) | 5.28 (0.68) | 5.34 (0.61) | 5.25 (0.64) | 0.879 |
| FFM (%) | 79.8 (2.8) | 78.7 (4.2) | 78.8 (3.7) | 0.524 |
WAZ, weight-for-age Z-score; HAZ, height-for-age Z-score; BAZ, Body mass index-for-age Z-score; R/H, Resistance/Height; Xc, Reactance/Height; FFM, fat-free mass. Continuous variables are presented as the means (standard deviations). 1 One-way ANOVA.